AIM: Microvascular free tissue transfer is a standard method in head and neck reconstructive surgery. However, previous radiotherapy of the operative region is associated with an increased incidence in postoperative flap-related complications and complete flap loss. As transforming growth factor beta (TGF-β) 1 and galectin-3 are well known markers in the context of fibrosis and lectin-like oxidized low-density lipoprotein 1 (LOX-1) supports vascular atherosclerosis, the aim of this study was to evaluate the expression of TGF-β1 and related markers as well as LOX-1 in irradiated vessels. MATERIALS AND METHODS: To evaluate the expression of galectin-3, Smad 2/3, TGF-β1, and LOX-1, 20 irradiated and 20 nonirradiated arterial vessels were used for immunohistochemical staining. We semiquantitatively assessed the ratio of stained cells/total number of cells (labeling index). RESULTS: Expression of galectin-3, Smad 2/3, and TGF-β1 was significantly increased in previously irradiated vessels compared with nonirradiated controls. Furthermore, LOX-1 was expressed significantly higher in irradiated compared with nonirradiated vessels. CONCLUSION: Fibrosis-related proteins like galectin-3, Smad 2/3, and TGF-β1 are upregulated after radiotherapy and support histopathological changes leading to vasculopathy of the irradiated vessels. Furthermore, postoperative complications in irradiated patients can be explained by increased endothelial dysfunction caused by LOX-1 in previously irradiated patients. Consequently, not only TGF-β1 but also galectin-3 inhibitors may decrease complications after microsurgical tissue transfer.
AIM: Microvascular free tissue transfer is a standard method in head and neck reconstructive surgery. However, previous radiotherapy of the operative region is associated with an increased incidence in postoperative flap-related complications and complete flap loss. As transforming growth factor beta (TGF-β) 1 and galectin-3 are well known markers in the context of fibrosis and lectin-like oxidized low-density lipoprotein 1 (LOX-1) supports vascular atherosclerosis, the aim of this study was to evaluate the expression of TGF-β1 and related markers as well as LOX-1 in irradiated vessels. MATERIALS AND METHODS: To evaluate the expression of galectin-3, Smad 2/3, TGF-β1, and LOX-1, 20 irradiated and 20 nonirradiated arterial vessels were used for immunohistochemical staining. We semiquantitatively assessed the ratio of stained cells/total number of cells (labeling index). RESULTS: Expression of galectin-3, Smad 2/3, and TGF-β1 was significantly increased in previously irradiated vessels compared with nonirradiated controls. Furthermore, LOX-1 was expressed significantly higher in irradiated compared with nonirradiated vessels. CONCLUSION:Fibrosis-related proteins like galectin-3, Smad 2/3, and TGF-β1 are upregulated after radiotherapy and support histopathological changes leading to vasculopathy of the irradiated vessels. Furthermore, postoperative complications in irradiated patients can be explained by increased endothelial dysfunction caused by LOX-1 in previously irradiated patients. Consequently, not only TGF-β1 but also galectin-3 inhibitors may decrease complications after microsurgical tissue transfer.
Authors: Thomas Mücke; Andrea Rau; Jochen Weitz; Andreas Ljubic; Nils Rohleder; Klaus-Dietrich Wolff; David A Mitchell; Marco R Kesting Journal: Oral Oncol Date: 2011-12-11 Impact factor: 5.337
Authors: Nicola S Russell; Saske Hoving; Sylvia Heeneman; J Joris Hage; Leonie A E Woerdeman; Remco de Bree; Peter J F M Lohuis; Ludi Smeele; Jack Cleutjens; Addy Valenkamp; Lucille D A Dorresteijn; Otilia Dalesio; Mat J Daemen; Fiona A Stewart Journal: Radiother Oncol Date: 2009-06-21 Impact factor: 6.280
Authors: Martin Halle; Anders Gabrielsen; Gabrielle Paulsson-Berne; Caroline Gahm; Hanna E Agardh; Filip Farnebo; Per Tornvall Journal: J Am Coll Cardiol Date: 2010-03-23 Impact factor: 24.094
Authors: Lucille D A Dorresteijn; Arnoud C Kappelle; Natasja M J Scholz; Marten Munneke; José T Scholma; Alfons J M Balm; Harry Bartelink; Willem Boogerd Journal: Eur J Cancer Date: 2005-05 Impact factor: 9.162
Authors: T Sugihara; Y Hattori; Y Yamamoto; F Qi; R Ichikawa; A Sato; M Y Liu; K Abe; M Kanno Journal: Circulation Date: 1999-08-10 Impact factor: 29.690
Authors: Stefan Schultze-Mosgau; Marcel A Blaese; Gerhard Grabenbauer; Falk Wehrhan; Jürgen Kopp; Kerstin Amann; H Peter Rodemann; Franz Rödel Journal: Radiother Oncol Date: 2004-03 Impact factor: 6.280
Authors: Patrick Möbius; Raimund H M Preidl; Manuel Weber; Kerstin Amann; Friedrich W Neukam; Falk Wehrhan Journal: Strahlenther Onkol Date: 2017-08-15 Impact factor: 3.621
Authors: Raimund H M Preidl; Patrick Möbius; Manuel Weber; Kerstin Amann; Friedrich W Neukam; Marco Kesting; Carol-Immanuel Geppert; Falk Wehrhan Journal: Strahlenther Onkol Date: 2018-10-15 Impact factor: 3.621
Authors: Salma K Jabbour; Terence M Williams; Mutlay Sayan; Eric D Miller; Jaffer A Ajani; Andrew C Chang; Norman Coleman; Wael El-Rifai; Michael Haddock; David Ilson; Daniel Jamorabo; Charles Kunos; Steven Lin; Geoffrey Liu; Pataje G Prasanna; Anil K Rustgi; Rosemary Wong; Bhadrasain Vikram; Mansoor M Ahmed Journal: J Natl Cancer Inst Date: 2021-06-01 Impact factor: 13.506